Retatrutide vs Tirzepatide
Mounjaro, Zepbound
Retatrutide (metabolic) and Tirzepatide (weight loss) are evaluated side by side on Vial: Retatrutide is investigational with clinical-trial evidence, and Tirzepatide is restricted with FDA-approval-level clinical evidence.
Vial summary · compiled from public records
At a glance
Tirzepatide
Sold as Mounjaro, Zepbound
- Category
- Weight Loss
- FDA / legal status
- Restricted
- Route
- Subcutaneous
Side by side
| Field | Retatrutide | Tirzepatide |
|---|---|---|
| Category | Metabolic | Weight Loss |
| Brand names | — | Mounjaro, Zepbound |
| FDA / legal status | Investigational | Restricted |
| Evidence tier | Clinical Trials | FDA Approved |
| Administration route | Subcutaneous | Subcutaneous |
| Compounding access | Investigational | Restricted |
| Providers on Vial | 0 listed | 23 listed |
| Typical price band | Varies by provider | $ to $$ |
Verified providers offering each
Ranked by Vial Score, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
Retatrutide0 top providers
No surfaceable providers currently list Retatrutide on Vial.
See all 0 providers offering retatrutide →About each compound
About Retatrutide
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, representing the most mechanistically advanced anti-obesity peptide in late-stage clinical development. Phase II trials reported mean body weight reductions of 24% over 48 weeks — the largest pharmacological weight loss ever recorded in a randomized controlled trial. It is being developed by Eli Lilly and is expected to enter Phase III trials in 2025–2026.
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.
Related compound comparisons
Other comparisons in the same category.